Quick Answer
Radiopharm Theranostics Ltd reported R&D Expense of $27.52 million for fiscal year 2025.
Radiopharm Theranostics Ltd R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $27.52M | +19.2% |
| 2024 | $23.09M | +2.0% |
| 2023 | $22.63M | — |
- Radiopharm Theranostics Ltd showed an increase of +19.2% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Radiopharm Theranostics Ltd’s r&d expense has grown by 21.6% (from $22.63 million to $27.52 million).
- The most recent figure is from Radiopharm Theranostics Ltd’s fiscal year 2025 report (Form 20-F), filed with the SEC on September 18, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: